Advertisement

Inappropriate sinus tachycardia–symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies

Published:October 07, 2017DOI:https://doi.org/10.1016/j.hrthm.2017.10.004

      Background

      Inappropriate sinus tachycardia (IST) is debilitating despite available treatment. Off-label use of ivabradine for IST prompted this systematic analysis of existing data quality and sample size estimates for adequately powered studies.

      Objective

      To determine clinical efficacy of ivabradine in IST from pooled prospective studies.

      Methods

      Analysis included ivabradine studies for IST participants without structural heart disease and with follow-up of ≥2 weeks. Heart rate and symptom reduction with ivabradine were estimated based on results of subjective change in symptoms assessed by various data instruments used in each study. Studies were assessed for quality using validated checklists. Sample sizes were calculated based on the magnitude of symptom reduction encountered after treatment with ivabradine.

      Results

      Nine studies met criteria, culminating in 145 patients pooled. Most patients were women (≥70%). Studies were small and not adequately powered, and all reported a decrease in maximum or mean resting heart rate or both, with complete or considerable amelioration of symptoms with ivabradine. Most studies had moderate quality with excellent consistency of study quality and narrow limits of agreement between the quality checklists. Sample size estimates for adequately powered studies with various placebo effects and comparisons with β-blockade are reported.

      Conclusions

      Ivabradine effectively reduces heart rate and symptoms in IST, but no study was adequately powered to account for the expected placebo effect on symptoms. A multicenter, randomized, placebo-controlled, active, comparative study with a β-blocker is needed for confirmation. This is especially relevant given the ivabradine’s potential teratogenic effect, as many IST patients are females of childbearing potential.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alboni P.
        • Malcarne C.
        • Pedroni P.
        • Masoni A.
        • Narula O.S.
        Electrophysiology of normal sinus node with and without autonomic blockade.
        Circulation. 1982; 65: 1236-1242
        • Swedberg K.
        • Komajda M.
        • Böhm M.
        • Borer J.S.
        • Ford I.
        • Dubost-Brama A.
        • Lerebours G.
        • Tavazzi L.
        • SHIFT Investigators
        Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
        Lancet. 2010; 11: 875-885
        • Still A.M.
        • Raatikainen P.
        • Ylitalo A.
        • Still A.M.
        • Raatikainen P.
        • Ylitalo A.
        Prevalence, characteristics and natural course of inappropriate sinus tachycardia.
        Europace. 2005; 7: 104-112
        • Brown H.F.
        • DiFrancesco D.
        • Noble S.J.
        How does adrenaline accelerate the heart?.
        Nature. 1979; 280: 235-236
        • Breithardt G.
        • Seipel L.
        • Loogen F.
        Sinus node recovery time and calculated sinoatrial conduction time in normal subjects and patients with sinus node dysfunction.
        Circulation. 1977; 56: 43-50
        • Beaulieu P.
        • Lambert C.
        Peptidic regulation of heart rate and interactions with the autonomic nervous system.
        Cardiovasc Res. 1998; 37: 578-585
        • Morillo C.A.
        • Klein G.J.
        • Thakur R.K.
        • Li H.
        • Zardini M.
        • Yee R.
        Mechanism of 'inappropriate' sinus tachycardia. Role of sympathovagal balance.
        Circulation. 1994; 90: 873-877
        • Callans D.J.
        • Schwartzman D.
        • Gottlieb C.D.
        • Marchlinski F.E.
        Insights into the electrophysiology of atrial arrhythmias gained by the catheter ablation experience: “learning while burning, Part II”.
        J Cardiovasc Electrophysiol. 1995; 6: 229-243
        • Vernino S.
        • Low P.A.
        • Fealey R.D.
        • Stewart J.D.
        • Farrugia G.
        • Lennon V.A.
        Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies.
        N Engl J Med. 2000; 343: 847-855
        • Marrouche N.F.
        • Beheiry S.
        • Tomassoni G.
        • Cole C.
        • Bash D.
        • Dresing T.
        • Saliba W.
        • Abdul-Karim A.
        • Tchou P.
        • Schweikert R.
        • Leonelli F.
        • Natale A.
        Three-dimensional nonfluoroscopic mapping and ablation of inappropriate sinus tachycardia. Procedural strategies and long-term outcome.
        J Am Coll Cardiol. 2002; 39: 1046-1054
        • Sheldon R.S.
        • Grubb II, B.P.
        • Olshansky B.
        • et al.
        2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope.
        Heart Rhythm. 2015; 12: e41-e63
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • PRISMA Group
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        Ann Intern Med. 2009; 151 (264–269, W64)
        • Downs S.H.
        • Black N.
        The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.
        J Epidemiol Community Health. 1998; 52: 377-384
        • Slim K.
        • Nini E.
        • Forestier D.
        • Kwiatkowski F.
        • Panis Y.
        • Chipponi J.
        Methodological index for non-randomized studies (minors): development and validation of a new instrument.
        ANZ J Surg. 2003; 73: 712-716
        • de Vet H.C.
        • Terwee C.B.
        • Knol D.L.
        • Bouter L.M.
        When to use agreement versus reliability measures.
        J Clin Epidemiol. 2006; 59: 1033-1039
        • Bland J.M.
        • Altman D.G.
        Statistical methods for assessing agreement between two methods of clinical measurement.
        Lancet. 1986; 1: 307-310
        • Costa-Santos C.
        • Bernardes J.
        • Ayres-de-Campos D.
        • Costa A.
        • Amorim-Costa C.
        The limits of agreement and the intraclass correlation coefficient may be inconsistent in the interpretation of agreement.
        J Clin Epidemiol. 2011; 64: 264-269
        • Fleiss J.
        The Design and Analysis of Clinical Experiments.
        John Wiley & Sons, New York1986: 8-43
        • Rakovec P.
        Treatment of inappropriate sinus tachycardia with ivabradine.
        Wien Klin Wochenschr. 2009; 121: 715-718
        • Cappato R.
        • Castelvecchio S.
        • Ricci C.
        • et al.
        Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation.
        J Am Coll Cardiol. 2012; 60: 1323-1329
        • Ptaszynski P.
        • Kaczmarek K.
        • Ruta J.
        • Klingenheben T.
        • Wranicz J.K.
        Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy.
        Europace. 2013; 15: 116-121
      1. Annamaria M; Sette A, Preiti S, Rebecchi M, de Ruvo E, Borrelli A, Scarà A, Fagagnini A, Nuccio F, Sciarra L, Calò L. Comparison of ivabradine and bisoprolol in the treatment of inappropriate sinus tachycardia. Paper presented at: Eleventh Annual Congress of the European Cardiac Arrhythmia Society; April 19, 2015; Paris, France.

        • Benezet-Mazuecos J.
        • Rubio J.M.
        • Farré J.
        • Quiñones M.Á.
        • Sanchez-Borque P.
        • Macía E.
        Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients.
        Pacing Clin Electrophysiol. 2013; 36: 830-836
        • Zellerhoff S.
        • Hinterseer M.
        • Felix Krull B.
        • Schulze-Bahr E.
        • Fabritz L.
        • Breithardt G.
        • Kirchhof P.
        • Kääb S.
        Ivabradine in patients with inappropriate sinus tachycardia.
        Naunyn Schmiedebergs Arch Pharmacol. 2010; 382: 483-486
        • Kaplinsky E.
        • Comes F.P.
        • Urondo L.S.
        • Ayma F.P.
        Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: a three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life assessments.
        Cardiol J. 2010; 17: 166-171
        • Hammond J.
        Inappropriate sinus tachycardia–experience with ivabradine.
        Heart Lung Circ. 2013; 22: S126-S266
        • Calò L.
        • Rebecchi M.
        • Sette A.
        • Martino A.
        • de Ruvo E.
        • Sciarra L.
        • De Luca L.
        • Zuccaro L.M.
        • Giunta G.
        • Ciccaglioni A.
        • Lioy E.
        • Fedele F.
        Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia.
        Heart Rhythm. 2010; 7: 1318-1323
        • Riccioni G.
        Ivabradine: recent and potential applications in clinical practice.
        Expert Opin Pharmacother. 2011; 12: 443-450
        • Ragueneau I.
        • Laveille C.
        • Jochemsen R.
        • Resplandy G.
        • Funck-Brentano C.
        • Jaillon P.
        Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers.
        Clin Pharmacol Ther. 1998; 64: 192-203
      2. Corlanor (ivabradine) [package insert]. Thousand Oaks, California: Amgen Inc.

        • Annamaria M.
        • Lupo P.P.
        • Foresti S.
        • De Ambroggi G.
        • de Ruvo E.
        • Sciarra L.
        • Cappato R.
        • Calo L.
        Treatment of inappropriate sinus tachycardia with ivabradine.
        J Interv Card Electrophysiol. 2016; 46: 47-53
        • Low P.A.
        Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure.
        Mayo Clin Proc. 1993; 68: 748-752